GLP-1 drugs and rising protein demand are steering capital, M&A and corporate investment toward functional, nutrient-dense products.
Cases in point: Last year, Kellanova introduced protein Pop-Tarts, PepsiCo announced protein Doritos and Starbucks debuted a protein-enhanced cold foam.
